Study On The Relationship Between The Expression Of ERCC1 And Oxaliplatin-based Chemotherapy Resistance In Advanced Colon Cancer

Objective: To explore the excision repair cross complementing-1(ERCC1) expression level in human advanced colon cancer, and analyze its relationship with the sensitivity of the platinum drugs and its prognosis.Methods: 44 cases of IV stage colon cance patients received oxaliplatin in first -line therapy,After failure or appears the chemotherapy dosage restrictive toxicity, received irinotecan in second-line therapy .Object two chemotherapies effective,Progression-free suivival(PFS) were assessed and Overall suivival(OS). The expression of ERCC-1 were examined.in tumor samples by the immunohisto- chemical supervision method ((Maxvision TM).Results:1. In first-line Chemotherapy 44 cases of patients ,their disease control rate was 27.3% in ERCC1 positive groupres pectively,and 59.1% in ERCC1 negative group respectively.There were significant difference between the two groups(P<0.05). In second-line Chemotherapy patients, their disease control rate was 4.5%,in ERCC1 positive groupres pectively,and 9% in ERCC1 negative group respectively.There were significant difference between the two groups(P>0.05).2. Revisit to 24 months, In first-line Chemotherapy patients ,The median PFS was 5 months in ERCC1 positive group respectively,and 11 months in ERCC1 Negative group respectively(P<0.05). In second-line Chemotherapy patients, The median PFS was 2.3 months in ERCC1 positive group respectively,and 2.6 months in ERCC1 Negative group respectively(X2=0.27,P=0.6010).3. In 44 cases of patients ,The median OS time was 13 months in ERCC1 positive group respectively , and 16 months in ERCC1 Negative group respectively(P<0.05).There was also significant difference between the two groups.4.After COX model of multi-factor regression analysis ,It found that patients with ERCC1 expression patients with advance colon cancer that affects the independence and possibility of the factors. Conclusion:1.In advanced colon cancer patients, ERCC1 negative expression group might obtained maximal benefit from using oxaliplatin-based chemotherapy.2.The level of ERCC1 expression was independent and possibility character of influencing factor to prognosis in advanced colon cancer.